Clinical Trials · NCT04325828
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Janssen Pharmaceutical K.K.
- Enrollment
- 31
- Start date
- Apr 2020
- Locations
- 7 sites, Japan
- Primary endpoint
- Overall Response Rate (ORR)